This inventor holds 4 USPTO granted patents and 4 published patent applications. Top assignee: Shilpa Medicare Limited. Active years: 2016-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Raichur, IN (2016 - 2017)
- Vizianagaram, IN (2017)
Company Filing History:
Years Active: 2016-2017
Title: Akshaykant Chaturvedi: Innovator in Pharmaceutical Science
Introduction
Akshaykant Chaturvedi is a notable inventor based in Raichur, India. He has made significant contributions to the field of pharmaceutical science, particularly in the development of active pharmaceutical ingredients. With a total of 4 patents to his name, Chaturvedi's work is recognized for its impact on medical treatments.
Latest Patents
Chaturvedi's latest patents include the formulation of 5-azacytidine. This invention relates to polymorphic forms of 5-Azacytidine and the process for its preparation. The crystalline form designated as Form-SA-1 is characterized by an X-ray powder diffraction pattern with specific diffraction angle peaks. This formulation is useful as an active pharmaceutical ingredient in treating myelodysplastic syndrome. Another significant patent is the process for the preparation of fingolimod and its salts. This invention provides a method for preparing Fingolimod hydrochloride, which may be beneficial in treating autoimmune-related disorders, including multiple sclerosis.
Career Highlights
Chaturvedi is currently associated with Shilpa Medicare Limited, a company known for its focus on pharmaceutical development. His work at the company has been instrumental in advancing innovative treatments in the pharmaceutical industry.
Collaborations
Chaturvedi has collaborated with notable colleagues, including Nagnnath Kokare and Rafiuddin Dr. Their combined expertise contributes to the success of their projects and innovations.
Conclusion
Akshaykant Chaturvedi stands out as a prominent inventor in the pharmaceutical field, with a focus on developing critical treatments for serious health conditions. His contributions continue to shape the landscape of pharmaceutical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile